Cogent Biosciences Reports Positive Clinical Trial Results

The latest update is out from Cogent Biosciences ( (COGT) ).

On December 6 and 8, 2025, Cogent Biosciences announced significant results from their clinical trials of bezuclastinib for systemic mastocytosis. The SUMMIT trial showed that bezuclastinib led to substantial improvements in patients with nonadvanced systemic mastocytosis, while the APEX trial demonstrated positive outcomes for those with advanced systemic mastocytosis. These results bolster Cogent’s position in the biotech industry and pave the way for a new drug application to the FDA, with potential implications for patients and stakeholders.

The most recent analyst rating on (COGT) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.

Spark’s Take on COGT Stock

According to Spark, TipRanks’ AI Analyst, COGT is a Underperform.

Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.

To see Spark’s full report on COGT stock, click here.

More about Cogent Biosciences

Cogent Biosciences is a company in the biotechnology industry, focusing on developing targeted therapies for genetically defined diseases. Their primary product is bezuclastinib, a treatment for systemic mastocytosis, with market focus on both nonadvanced and advanced forms of the disease.

Average Trading Volume: 3,085,229

Technical Sentiment Signal: Buy

Current Market Cap: $5.9B

Find detailed analytics on COGT stock on TipRanks’ Stock Analysis page.